Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04811625 · ClinicalTrials.gov registry record · Phase 4
Pharmacodynamic and Pharmacokinetic Study of PL-ASA
A Phase 4 study, sponsored by PLx Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT04811625 is a Phase 4 study that has completed, run by PLx Pharma. The registered enrollment target is 36 participants.
The verdict
NCT04811625, a Phase 4 study, has completed, sponsored by PLx Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
A randomized, open-label, 2-way crossover pharmacodynamic and pharmacokinetic study of a novel pharmaceutical lipid-aspirin complex formulation (PL-ASA) at an 81 mg dose
Interventions
- DRUG PL-ASA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2021-09-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04811625
The ClinicalTrials.gov registry entry for NCT04811625 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PLx Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PL-ASA is the first listed.
NCT04811625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04811625 about?
NCT04811625 is a clinical study titled "Pharmacodynamic and Pharmacokinetic Study of PL-ASA". A randomized, open-label, 2-way crossover pharmacodynamic and pharmacokinetic study of a novel pharmaceutical lipid-aspirin complex formulation (PL-ASA) at an 81 mg dose
What is the current status of trial NCT04811625?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2021-04-28. Estimated completion is 2021-09-15.
What interventions are being tested in trial NCT04811625?
The interventions under investigation include: PL-ASA (DRUG).
Who is sponsoring clinical trial NCT04811625?
This trial is sponsored by PLx Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.